A Novel Blended Hybrid Care Model for Maternal Mental Health: Cohort Study of Pregnant and Postpartum Patients

BackgroundPerinatal mood and anxiety disorders are the most common complications of pregnancy. Given the limited mental health resources, there is a need for novel treatment approaches. Though smartphone applications can increase access to evidence-based care, recent research highlights notable limitations, including varying quality and unclear effectiveness. Blended hybrid care models, which integrate synchronous telehealth services with asynchronous modalities (such as mobile apps), have emerged as an alternative. This pilot study evaluates one such model, the Digital Clinic, to determine its potential to bridge this critical treatment gap and compare outcomes to that of non-peripartum patients in the clinic. MethodsPregnant and postpartum women referred for anxiety and depression received 8 weeks of synchronous, virtual, evidence-based CBT from a trained clinician. This treatment was complemented by the asynchronous use of the mindLAMP app, providing digital phenotyping, psychoeducation, and CBT skills, with the support of a Digital Navigator. The efficacy of the intervention was evaluated by comparing GAD-7 and PHQ-9 scores from intake to the end of treatment. ResultsThis secondary analysis included 13 peripartum women from a larger sample of 224 clinic patients. At intake, they reported a mean PHQ-9 score of 9.4 (SD=3.9) and a mean GAD-7 score of 11.69 (SD=6.0). After 8 weeks, participants reported statistically significant decreases of 4.14 points on the GAD-7 (p<.01) and 3.92 points on the PHQ-9 (p<.01). Effect sizes for these reductions were 0.74 (95% CI: 0.20, 1.28) for GAD-7 and 1.10 (95% CI: 0.29, 1.90) for PHQ-9. ConclusionA novel blended hybrid care model, the Digital Clinic, was successful in reducing depression and anxiety among pregnant and postpartum women. This novel approach to maternal mental health shows promise for delivering accessible, effective, evidence-based care to peripartum patients in real-world settings. Future work should further validate its effectiveness with larger, more diverse patient populations with moderate to severe disease.